Welcome to our dedicated page for MBX Biosciences SEC filings (Ticker: MBX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The MBX Biosciences, Inc. (Nasdaq: MBX) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a clinical-stage biopharmaceutical company and emerging growth company, MBX uses filings such as Forms S-1, 10-K, 10-Q, and 8-K to describe its Precision Endocrine Peptide™ (PEP™) platform, clinical programs, risk factors, and capital-raising activities.
In its S-1 registration statement, MBX outlines its focus on novel precision peptide therapies for endocrine and metabolic disorders and details key product candidates, including canvuparatide (MBX 2109) for chronic hypoparathyroidism, imapextide (MBX 1416) for post-bariatric hypoglycemia, and MBX 4291 for obesity. Subsequent 8-K filings report material events such as topline results from the Phase 2 Avail™ trial of canvuparatide, initiation of the Phase 1 trial of MBX 4291, public equity offerings, and changes in board and committee roles.
Through this page, users can review MBX’s periodic financial reports, which discuss research and development spending, cash and marketable securities, and expectations about funding operations, as well as prospectus materials that describe intended uses of offering proceeds. Form 8-K filings also summarize key clinical data, trial designs, and future development plans for the company’s programs.
Stock Titan enhances these filings with AI-powered summaries that highlight the main points of lengthy documents, helping readers quickly understand topics such as clinical results, financing terms, and governance updates. Real-time updates from EDGAR, along with structured access to material event reports and registration statements, make this page a central resource for analyzing MBX’s regulatory and financial disclosures.
MBX Biosciences, Inc. reports that Chief Executive Officer and director Kent P. Hawryluk will leave both roles effective July 13, 2026. He will provide transition and strategic advisory services as a consultant through August 16, 2026. His separation terms include 12 months of base-salary severance, up to 12 months of Company-paid COBRA continuation coverage, a cash bonus equal to his target annual bonus, accelerated vesting of time-based equity that would have vested through August 16, 2027, and an extension of the post-termination stock option exercise period to July 13, 2027. The company states his departure is not due to a dispute or disagreement.
The Board appointed executive chairman Steven Hoerter as President, Chief Executive Officer and principal executive officer effective July 13, 2026, with a base salary of $665,000, a target annual bonus equal to 60% of base salary, options to purchase 331,000 shares and 71,000 RSUs, subject to multi‑year vesting. Interim Chief Financial Officer John Smither was named Chief Financial Officer and principal financial officer, effective the same date, with a $530,000 base salary, 40% target bonus, a $150,000 relocation bonus, options on 130,000 shares and 28,000 RSUs, also subject to multi‑year vesting.
MBX Biosciences ownership filing: Wellington Management Group LLP and affiliated Wellington entities report beneficial ownership of 4,977,523 shares of MBX Biosciences common stock, representing 10.46% of the class. The filing lists shared voting and dispositive powers across named Wellington entities and identifies the shares as owned of record by clients of Wellington investment advisers.
MBX BIOSCIENCES INC filed an Amendment (Schedule 13G/A) disclosing that FMR LLC beneficially owns 5,322,884.68 shares of common stock, representing 11.2% of the class as of 06/30/2026. The filing lists Abigail P. Johnson as having dispositive power over the same 5,322,884.68 shares. The report is signed under a power of attorney and references an attached 13d-1(k)(1) agreement in Exhibit 99.
MBX Biosciences reports institutional holdings disclosed on a Schedule 13G showing Paradigm-related reporting persons beneficially owning disclosed stakes as of June 16, 2026.
The filing lists Paradigm BioCapital Advisors, Paradigm BioCapital Advisors GP LLC, Senai Asefaw, M.D., and Paradigm BioCapital International Fund Ltd. with reported sole voting and dispositive power over specified share counts. The ownership percentages use an outstanding share base of 47,597,536 shares as of May 4, 2026.
MBX Biosciences reported one-year Phase 2 and open-label extension data for once-weekly canvuparatide in adults with chronic hypoparathyroidism. In the 12-week Avail trial, 63% of canvuparatide-treated patients (30/48) met the primary composite endpoint versus 31% on placebo (5/16), showing better control of calcium with reduced dependence on supplements. At one year, 57% of evaluable patients (31/54) were responders with no rescue therapy used in the final week, and 90% of patients entering the extension remained on treatment, indicating strong durability and retention.
Pharmacokinetic data showed a Tmax of 2–3 days and a peak‑to‑trough ratio around 1.3, supporting stable once-weekly dosing. Mean serum calcium stayed in the normal range while 24‑hour urine calcium fell and remained normal, kidney function (eGFR) improved, and bone turnover markers and bone mineral density shifted in patterns consistent with physiologic PTH replacement. Canvuparatide was generally well tolerated through one year, with most adverse events mild or moderate, no treatment-related serious events, and injection site reactions in 10% of patients. MBX plans to start a Phase 3 pivotal trial in Q3 2026 and reports about $440 million in cash, cash equivalents and marketable securities as of March 31, 2026, which it estimates will fund operations into 2029.
Richard B. Bartram reported a proposed sale of 9,167 shares of Common Stock related to a stock option exercise, planned for 06/10/2026 and to be processed through Fidelity Brokerage Services LLC on NASDAQ for cash. The filing also lists multiple open-market dispositions by Mr. Bartram during the prior three months, including sales on 05/11/2026 (22,500 shares) and 06/09/2026 (10,833 shares).
MBX officer reported proposed sales of common stock under Form 144 related to stock option exercises and prior open-market dispositions. The filing lists multiple sales and proposed sale activity, including individual transactions on 03/16/2026, 03/25/2026, 04/22/2026, and several dates in May and June 2026.
MBX Biosciences director Edward T. Mathers received a new stock option grant covering 12,500 shares of common stock. The option has an exercise price of $30.91 per share and expires on June 4, 2036. Following this grant, he holds 12,500 stock option rights directly.
The grant vests in full on the earlier of the one-year anniversary of the grant date or the date of the company’s next annual meeting of stockholders, as long as he continues serving as a non-employee director.
MBX Biosciences director Ora H. Pescovitz received a grant of stock options, reflecting equity-based compensation rather than an open-market trade. The award covers 12,500 options to buy common stock at an exercise price of $30.91 per share, expiring on June 4, 2036.
According to the terms, the grant will vest in full on the earlier of the one-year anniversary of the grant date or the company’s next annual stockholder meeting, subject to her continued service as a non-employee director. Following this filing, she also holds 24,329 shares of common stock directly.
MBX Biosciences, Inc. director and ten percent owner Patrick J. Heron received a grant of stock options covering 12,500 shares of common stock. The options have an exercise price of $30.91 per share and expire on June 4, 2036.
The grant will vest in full on the earlier of the one-year anniversary of the grant date or the date of the company’s next annual meeting of stockholders, as long as the non-employee director continues to provide services. This is a compensation-related award rather than an open-market share purchase or sale.